Alerts
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
A Year of Measles in Utah Is What Lost Protection Looks Like
Do Not Turn Cancer Trials Into Political Collateral
A Seizure Diagnosis Should Not Automatically End a Career
Bird Flu Reached Australia. Now Preparedness Has to Deliver.
Measles Is Finding the Holes in America’s Protection Map
Gastric Cancer Gets a New Biomarker Access Signal
Brain-Bleed Care Still Has a Last-Mile Problem
Hepatitis A Shows What Happens When Water Systems Fail People
Ebola Funding Finally Moves. The Virus Has Already Moved Faster.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.